Comparison of the impact of the Tobacco Heating System 2.2 and a cigarette on indoor air quality


Authored by  M Mitova, P B Campelos, C Goujon-Ginglinger, S Maeder, N Mottier, E G R Rouget, M Tharin, A R Tricker

Published in Regulatory Toxicology and Pharmacology     Volume 80, October 2016, Pages 91-101

Abstract

The impact of the Tobacco Heating System 2.2 (THS 2.2) on indoor air quality was evaluated in an environmentally controlled room using ventilation conditions recommended for simulating “Office”, “Residential” and “Hospitality” environments and was compared with smoking a lit-end cigarette (Marlboro Gold) under identical experimental conditions. The concentrations of eighteen indoor air constituents (respirable suspended particles (RSP) < 2.5 μm in diameter), ultraviolet particulate matter (UVPM), fluorescent particulate matter (FPM), solanesol, 3-ethenylpyridine, nicotine, 1,3-butadiene, acrylonitrile, benzene, isoprene, toluene, acetaldehyde, acrolein, crotonaldehyde, formaldehyde, carbon monoxide, nitrogen oxide, and combined oxides of nitrogen) were measured. In simulations evaluating THS 2.2, the concentrations of most studied analytes did not exceed the background concentrations determined when non-smoking panelists were present in the environmentally controlled room under equivalent conditions. Only acetaldehyde and nicotine concentrations were increased above background concentrations in the “Office” (3.65 and 1.10 μg/m3), “Residential” (5.09 and 1.81 μg/m3) and “Hospitality” (1.40 and 0.66 μg/m3) simulations, respectively. Smoking Marlboro Gold resulted in greater increases in the concentrations of acetaldehyde (58.8, 83.8 and 33.1 μg/m3) and nicotine (34.7, 29.1 and 34.6 μg/m3) as well as all other measured indoor air constituents in the “Office”, “Residential” and “Hospitality” simulations, respectively.

Our Findings

We are committed to sharing our results as the development and scientific assessment of our products advance. Read our most important findings with supporting peer-reviewed articles, presentations, and registered clinical trials.

What we have learned so far...